

## **Product** Data Sheet

## **Crozbaciclib fumarate**

Cat. No.: HY-112280A CAS No.: 2567494-39-5 Molecular Formula:  $C_{32}H_{34}F_2N_6O_4$  Molecular Weight: 604.65

Target: CDK

Pathway: Cell Cycle/DNA Damage

**Storage:** Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

| Description               | Crozbaciclib fumarate is a CDK4/6 inhibitor with IC $_{50}$ s of 3 and 1 nM, respectively.   |
|---------------------------|--|
| IC <sub>50</sub> & Target | IC50: 3 nM (CDK4), 1 nM (CDK6) <sup>[1]</sup>  |
| In Vitro                  | Crozbaciclib fumarate is a potent anti-proliferative agent that arrests U87MG cell line exclusively in G1 (IC $_{50}$ =15.3 ± 2.9 nM in the anti-proliferation assay). Crozbaciclib fumarate (13.72 nM; 24 h) significantly increases in the percentage of cells in G1 in U87MG cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.   |
| In Vivo                   | Crozbaciclib fumarate (3.125-50 mg/kg) has tumor growth inhibition values ranging from 62% to 99% in an orthotopic xenograft mouse model of glioblastoma multiforme. And Crozbaciclib fumarate results insignificant body weight loss. Crozbaciclib fumarate increases life span based on the median survival time of vehicle-treated animals in mice is significant at 162%, at a dose of 50 mg/kg $^{[1]}$ . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## **REFERENCES**

[1]. Yin L, et al. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. Eur J Med Chem. 2018 Jan 20;144:1-28.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA